Amsterdam-based NGO Access To Medicine Foundation (AMF) has published the fourth edition of its Antimicrobial Resistance Benchmark report. Chief Executive Officer, Jayasree K. Iyer, says that there are some positive signs with recent regulatory approvals for three antibiotics with innovative characteristics and seven promising products in late-stage development, but that overall the pipeline remains “worryingly thin” and far from picking up pace “industry investment has lost momentum”.

Smaller firms filling innovation gap
The report covers 25 companies, including large and – for the first time – small companies, and ten generic manufacturers. It focuses on three main areas: R&D, responsible manufacturing and appropriate access and stewardship.

The authors estimate that the number of projects from large research-based pharmaceutical companies has declined by 35% between…